Medicinal composition containing realgar

A composition and technology of realgar, applied in the field of anti-tumor drugs, can solve the problems of reducing toxicity, achieve low toxicity and improve the effect of anti-tumor effect

Active Publication Date: 2011-07-13
李红玉
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the efficacy of realgar solution is still possible to b...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing realgar

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] The preparation and quality control of each component of embodiment 1 medicine

[0017] Preparation of realgar dissolving solution: prepared according to the bacterial treatment method disclosed in Chinese invention patent application number 2006102000675. Use the leaching microorganism Thiobacillus ferrooxidans to process the realgar powder biologically. The realgar is at a room temperature of about 30°C, the particle size is 180-200 mesh, the pulp concentration is 1%, and the initial Fe 2+ The concentration is 1.0g / L, the pH value of the slurry is 2.2, the bacterial inoculum is 20%, the flask is shaken at 130rpm for 30 days, filtered, and the filtrate is the realgar solution. The total arsenic content of the solution was determined to be 1590 μg / ml by inductively coupled plasma atomic emission spectrometry (ICP-AES). Dilute to 32μg / ml before use, and set aside.

[0018] Preparation of matrine solution: take 50 mg of matrine, dissolve in 5 ml of distilled water to ma...

Embodiment 2

[0022] The inhibitory action of embodiment two realgar dissolving solution to nematode Let-60

[0023] Material: C. elegans: Let-60(n1046)IV

[0024] M solution: 15g Na per liter of buffer 2 HPO 4 12H 2 O, 3g KH 2 PO 4 , 5g NaCl, 0.25g MgSO 4 ·7H 2 O.

[0025] Principle: Studies have found that about 30% of human tumors have mutation activation of Ras gene and increased expression of Ras protein (Signal-Transduction[M].2005: 20-100). source let-60 Caenorhabditis elegans mutant, the effects of two Ras farnesyltransferase inhibitors on the Ras pathway were investigated, and the results showed that the two Ras farnesyltransferase inhibitors can downregulate the hyperactivity of the Ras pathway Activated, let-60 mutant nematodes with a polyvulva phenotype become wild-type under the action of drugs (PNAS 1995:92:3333-3337.). Therefore, Caenorhabditis elegans polyvulva phenotype mutants have been widely adopted as model organisms for anti-cancer gene Ras active drug screeni...

Embodiment 3

[0034] The effect of embodiment three realgar dissolving liquid compositions on Let-60

[0035] Experimental procedure: with embodiment two

[0036] LC50 experimental procedure: same as embodiment two

[0037] Composition of realgar dissolving solution: 40% realgar dissolving solution, 0.8% matrine, 0.8% ginseng extract, 0.8% astragalus extract, M solution supplemented to 100%. The experimental results are shown in Table 2:

[0038] The effect of table 2 realgar dissolving solution composition on Let-60

[0039] group

[0040] Note: Compared with the blank group *P<0.05

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Granularityaaaaaaaaaa
Login to view more

Abstract

The invention provides a medicinal composition containing realgar. Particularly, the medicinal composition contains realgar microbiological leaching liquid, a ginseng extract, an astragalus extract and oxymatrine. An animal experiment shows that the medicinal composition has an obvious down-regulation effect on excessive activation of a path of a proto-oncogene Ras and low toxicity; therefore, the medicinal composition is suitable to be applied in the preparation of an antineoplastic medicine.

Description

technical field [0001] The invention provides a pharmaceutical composition containing realgar. Specifically, the pharmaceutical composition contains realgar dissolving solution, ginseng extract, astragalus extract and matrine, and belongs to the field of antitumor drugs. Background technique [0002] In September 2000, the U.S. FDA approved the As 2 o 3 The injection is used for the treatment of refractory and relapsed acute promyelocytic leukemia. Studies at home and abroad have shown that arsenic not only has a significant effect on hematological tumors, but also can be used to treat other malignant solid tumors. Therefore, the treatment of cancer by arsenic preparations has attracted more attention, and the development and application of arsenic-containing preparations has become a hot spot in the research of anti-tumor drugs, but whether it is As 2 o 3 Injection or other arsenic-containing preparations have a common problem of high toxicity. [0003] As a mineral me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/481A61P35/00A61K31/4375A61K33/36
Inventor 李红玉刘东玲支德娟
Owner 李红玉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products